פרסומים - ד"ר מיכל בסר
List of Publications, Besser MJ.
1. Besser M and Wank R.
Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol. 162:6303-6306, 1999
2. Eshel R, Besser M, Zanin A, Sagi-Assif O and Witz IP.
The FX enzyme is a functional component of lymphocyte activation. Cell Immuno. 213:141-148, 2001
3. Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R and Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates ß1 integrin function. Eur J Immunol. 31:3504-3512, 2001
4. Ganor Y *, Besser M * (*equal contribution), Ben-Zakay N, Unger T and Levite M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration.
J Immunol. 170:4362-4372, 2003
5. Besser MJ, Ganor Y and Levite M.
Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both.
J Neuroimmunol. 169:161-171, 2005
6. Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B and Schachter J.
Adoptive cell therapy for metastatic melanoma patients: Pre-clinical development at the Sheba Medical Center.
Isr Med Assoc J. 8:164-168, 2006
7. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A and Schachter J.
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
J Immunol. 177:6062-71, 2006
8. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, Nagler A, Schachter J. Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine.
J Immunother. 31:563-8, 2008
9. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, Orenstein A, Berger R, Schachter J.
Dynamic expression of protective CEACAM-1 on melanoma cells during specific immune attack.
Immunology. 126:186-200, 2009
10. Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y and Schachter J.
Modifying IL-2 concentrations during culture improves function of T-cells for adoptive immunotherapy.
Cytotherapy. 11:206-17, 2009
11. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Treves AJ, Freidman E, Keisari Y, Dotan Z, Ramon J and Schachter J.
Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
Anticancer Research. 29:145-154, 2009
12. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Ben Nun A, Kuchuk I, Shimoni A, Nagler A and Schachter J.
Minimally-cultured or selected autologous tumor infiltrating lymphocytes following a lymphodepleting chemotherapy regimen in metastatic melanoma patients.
J Immunother. 32:415-23, 2009
13. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Loewenthal R, Orenstein A, Nagler A and Schachter J.
Natural Killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK Cells.
PLoS ONE. 4:e5597, 2009
14. Oved K, Eden E, Akerman M, Noy R, Wolchinsky R, Izhaki O, Schallmach E, Kubi A, Zabari N, Schachter J, Alon U, Mandel-Gutfreund Y, Besser MJ * and Yoram Reiter * (*corresponding authors).
Featured article: Predicting and controlling the reactivity of immune cell populations in cancer.
Mol Syst Biol. 5:265, 2009
Selected for "Editors' Choice": Highlights of the recent literature. 2009. Science. 324:569.
15. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J.
Systemic dysregulation of CEACAM1 in melanoma patients.
Cancer Immunol. Immunother. 59:215-30, 2010
16. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A and Schachter J.
Clinical responses in a phase II Study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
Clin Cancer Res. 2010. 16:2646-55.
17. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zickich D, Hershkovitz L, Treves AJ, Shalmon B, Markel G, Schachter J, Besser MJ.
Establishment and large-scale expansion of minimally-cultured "Young" Tumor Infiltrating Lymphocytes (TIL) for adoptive transfer therapy.J Immunother. 2011. In Press.
18. Hershkovitz L, Schachter J, Treves AJ and Besser MJ.
Focus on adoptive T cell transfer trials in melanoma.
Clin and Devel Immunol. 2011. In Press
